Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix.
Sixty-one evaluable patients with advanced squamous cell carcinoma of the cervix were treated in a randomized fashion with either doxorubicin, vincristine, and 5-FU in combination (AVF) or with cyclophosphamide (CTX). Of 31 patients treated with AVF, only three (10%) responded (one complete response and two partial responses). Of 30 patients treated with CTX, there were two (7%) with partial responses. Two patients responded to AVF after failing CTX; one patient responded to CTX after failing AVF. Neither of these regimens was predictably useful in our patient population.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003520:Cyclophosphamide; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D011897:Random Allocation; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil